Prabhakar Tiwari

Dr. Prabhakar Tiwari


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PTPrabhakar Tiwari
Prabhakar Tiwari
RDRekha Dwivedi
Rekha Dwivedi
MBManisha Bansal
Manisha Bansal
MTManjari Tripathi
Manjari Tripathi
RDRima Dada
Rima Dada
In humans, the gut microbiota (GM) are known to play a significant role in the metabolism of nutrients and drugs, immunomodulation, and pathogen defense by inhabiting the gastrointestinal tract (GIT). The role of the GM in the gut–brain axis (GBA) has been documented for different regulatory mechanisms and associated pathways and it shows different behaviors with individualized bacteria. In addition, the GM are known as susceptibility factor for neurological disorders in the central nervous system (CNS), regulating disease progression and being amenable to intervention. Bidirectional transmission between the brain and the GM occurs in the GBA, implying that it performs a significant role in neurocrine, endocrine, and immune-mediated signaling pathways. The GM regulates multiple neurological disorders by supplementing them with prebiotics, probiotics, postbiotics, synbiotics, fecal transplantations, and/or antibiotics. A well-balanced diet is critically important for establishing healthy GM, which can alter the enteric nervous system (ENS) and regulate multiple neurological disorders. Here, we have discussed the function of the GM in the GBA from the gut to the brain and the brain to the gut, the pathways associated with neurology that interacts with the GM, and the various neurological disorders associated with the GM. Furthermore, we have highlighted the recent advances and future prospects of the GBA, which may require addressing research concerns about GM and associated neurological disorders.

18 July 2024 in Brain Research
Verified
Journal Article
Closed access
RDRekha Dwivedi
Rekha Dwivedi
MKMeenakshi Kaushik
Meenakshi Kaushik
MTManjari Tripathi
Manjari Tripathi
RDRima Dada
Rima Dada
PTPrabhakar Tiwari
Prabhakar Tiwari

14 October 2022 in Heliyon
Verified
Journal Article
Open access
RDRekha Dwivedi
Rekha Dwivedi
PTPrabhakar Tiwari
Prabhakar Tiwari
MPMonika Pahuja
Monika Pahuja
RDRima Dada
Rima Dada
MTManjari Tripathi
Manjari Tripathi
The goal of this study was to determine the effects of mono-, bi-, and polytherapy anti-seizure medications (ASMs) in terms of seizure reduction and quality of life (QOL) in persons with epilepsy (PWE). A cross-sectional observational study was conducted. All PWE with age <75 years were recruited and further classified into two groups: responders and non-responders, based on the response of the ASMs to the treatments for reduced seizure frequency since the last one year. Other demographic and clinical data such as seizure frequency, type of seizures, age at onset of seizures, and information about ASMs with their daily doses were assessed for the descriptive analysis. The quality of life was assessed in randomly selected PWE (n = 100) using the quality of life in epilepsy inventory-31 (QOLIE-31) in adults. With a total of 486 PWE, the median age (years) was comparable in both groups. Out of these the non-responders group was found to be significantly higher (77.8%) than the responders group (22.2%). In the responders group, the percentage of PWE who were on monotherapy was significantly higher (51.85 %) than those who were on polytherapy (17.59%), whereas in the non-responders group, 21.16% of PWE were on monotherapy and 44.86% were on polytherapy. The duration of epilepsy was similar in both groups, but the average seizure frequency was significantly higher in the non-responders. In QOL assessments, 43% of PWE were observed in the responders group, whereas 57% of PWE were found in the non-responders group. The overall comparative QOL scores were also significantly higher (p < 0.0001) in the responders group as compared to the non-responders group. Our findings revealed that those PWE who were on monotherapy showed better reduction in seizure frequency and improved QOL in responder groups as compared to non-responder groups.

1 January 2024 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
STShashank Tripathi
Shashank Tripathi
MKMeenakshi Kaushik
Meenakshi Kaushik
RDRekha Dwivedi
Rekha Dwivedi
PTPrabhakar Tiwari
Prabhakar Tiwari
MTManjari Tripathi
Manjari Tripathi
RDRima Dada
Rima Dada
Background: Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are progressive neurodegenerative disorders, and probiotics may offer therapeutic benefits by modulating gut microbiota and reducing inflammation. Objective: This study systematically evaluated the impact of probiotics on cognitive function in MCI and AD through a meta-analysis of randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were performed following PRISMA 2020 guidelines. PubMed, Embase, EBSCO, and Cochrane databases were searched for RCTs (January 2000–January 2024) on probiotic interventions lasting 8–24 weeks. Cognitive outcomes included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), language, naming, visual-spatial, memory, and attention. Data were analyzed using R with a random-effects model to calculate pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs). Risk of bias was rigorously assessed. Results: Out of 2000 articles, 500 full texts were screened, and 10 studies were included. The meta-analysis showed varied effect sizes: MMSE (SMD: 0.28, 95%CI −0.35–0.91, p = 0.38), MoCA (SMD: 0.51, 95%CI −0.49–1.52, p = 0.33), language (SMD: −0.12, 95% CI −0.54–0.29, p = 0.56), naming (SMD: 0.02, 95%CI −0.69–0.74, p = 0.95), visual-spatial (SMD: 0.38, 95%CI −0.13–0.88, p = 0.14), memory (SMD: 0.20, 95%CI −0.15–0.55, p = 0.26), and attention (SMD: −0.07, 95%CI −0.44–0.30, p = 0.71). Positive SMDs suggest cognitive improvement, while non-significant negative SMDs indicate trends toward decline, inclined by probiotic strains, duration, and participant characteristics. Conclusions: Probiotics did not significantly improve cognitive function in MCI and AD patients, with variability in effects across cognitive domains, suggesting the need for tailored interventions and future studies.

18 October 2025 in Brain Communications
Verified
Journal Article
Open access
PTPrabhakar Tiwari
Prabhakar Tiwari
AGAnu Gupta
Anu Gupta
MKMeenakshi Kaushik
Meenakshi Kaushik
AYAnjali Yadav
Anjali Yadav
AAAnjali Anjali
Anjali Anjali
RDRima Dada
Rima Dada
Alzheimer’s disease is a multifactorial neurodegenerative disorder marked by cognitive decline, synaptic dysfunction, and metabolic alterations. This study investigated disease-associated profiles in the Indian population using integrated clinical, metabolomic, and plasma biomarker analyses. We enrolled 25 clinically diagnosed patients (mean age: 61.20 ± 7.76 years) and 25 cognitively healthy controls (mean age: 60.56 ± 7.48 years). Cognitive and neuropsychiatric assessments included Addenbrooke’s Cognitive Examination-III, Clinical Dementia Rating-Global, and Patient Health Questionnaire-9 for patients, and Montreal Cognitive Assessment, Clinical Dementia Rating-Global, and Patient Health Questionnaire-9 for controls. Plasma metabolomics was performed using liquid chromatography–mass spectrometry, and targeted ELISA quantified amyloid beta 40, amyloid beta 42, phosphorylated tau181, phosphorylated tau217, neurofilament light chain, apolipoprotein E, APOE4, 8-hydroxy-2′-deoxyguanosine, C-reactive protein, brain-derived neurotrophic factor, and glutamate. Statistical analyses included principal component analysis, volcano plots, receiver operating characteristic curves, pathway enrichment, and correlation analyses. Patients showed reduced cognition (median Addenbrooke’s Cognitive Examination-III: 26). Clinical Dementia Rating-Global scores (1.44 ± 0.65 versus 0.24 ± 0.25; P < 0.0001) and Patient Health Questionnaire-9 scores (4.88 ± 4.21 versus 0.20 ± 0.50; P < 0.0001) were higher than controls. Principal component analysis revealed distinct metabolic clustering with 75 altered metabolites. Volcano analysis identified six upregulated (leucine, ascorbic acid, guanine) and 14 downregulated metabolites (valine, nicotinamide, octadecanedicarboxylic acid). Receiver operating characteristic curves highlighted octadecanedicarboxylic acid (AUC = 0.917), prolinamide (AUC = 0.908), 2-phosphoglycerate (AUC = 0.858), nicotinamide (AUC = 0.848), leucine (AUC = 0.768), and ascorbic acid (AUC = 0.748). Pathway enrichment indicated disruptions in branched-chain amino acid metabolism, nicotinamide metabolism, the tricarboxylic acid cycle, and neurotransmitter pathways. Biomarker analysis revealed elevated amyloid beta 40, amyloid beta 42/40 ratio, phosphorylated tau181, phosphorylated tau217, phosphorylated tau217/amyloid beta 42 ratio, neurofilament light chain, APOE4, C-reactive protein, and 8-hydroxy-2′-deoxyguanosine, with reduced brain-derived neurotrophic factor (all P < 0.05). Significant correlations included eupatilin with phosphorylated tau217 and 8-hydroxy-2′-deoxyguanosine, glyceraldehyde with brain-derived neurotrophic factor, guanine with APOE4, and valine inversely with phosphorylated tau181. This study identifies distinct metabolic (octadecanedicarboxylic acid, prolinamide, leucine, ascorbic acid) and biomarker profiles (phosphorylated tau217, 8-hydroxy-2′-deoxyguanosine, brain-derived neurotrophic factor) in Alzheimer’s disease. Disrupted pathways linked to neuroinflammation and oxidative stress support the potential for integrated early detection strategies. Despite the small cross-sectional cohort, findings highlight the need for longitudinal, multi-centric validation.

21 March 2025 in Frontiers in Aging
Verified
Journal Article
Open access
PDF file
MKMeenakshi Kaushik
Meenakshi Kaushik
AYAnjali Yadav
Anjali Yadav
AUAshishdatt Upadhyay
Ashishdatt Upadhyay
AGAnu Gupta
Anu Gupta
PTPrabhakar Tiwari
Prabhakar Tiwari
RDRima Dada
Rima Dada
Background and objective: Alzheimer’s disease (AD) presents profound challenges, significantly impairing quality of life (QOL) for patients and increasing the burden on caregivers. This study aims to investigate the effectiveness of a tailored 12-week yoga intervention in improving the quality of life for individuals with mild to moderate AD and reducing caregiver burden (CB).Methods: This is yoga interventional study with healthy controls enrolled 30 participants (18 males, 12 females) diagnosed with mild to moderate AD by an expert neurologist. Participants were aged 60 years or older and were recruited from an old age home. A 12-week yoga program, including specific postures (asanas), pranayama (breathing exercises), and meditation, was conducted for 1 hour daily, 6 days a week. Neurocognitive assessments were performed pre- and post-intervention using the Geriatric Depression Scale (GDS), Montreal Cognitive Assessment (MoCA), and Caregiver Burden (CB) Scale. MoCA scores were analyzed across specific domains, including language, memory, attention, visuospatial ability, delayed recall, abstraction, and orientation.Results: The intervention led to significant improvements in quality-of-life measures. GDS scores decreased from 8.36 ± 2.79 to 5.13 ± 3.07 (P < 0.01; 95% CI: −3.98 to −2.31), while MoCA total scores improved from 18.23 ± 4.90 to 21.10 ± 5.09 (P < 0.01; 95% CI: 2.17–3.89). Domain-specific MoCA scores also showed significant enhancements, particularly in language, attention, and delayed recall. Caregiver burden, measured using the CB Scale, demonstrated notable reductions following the intervention (P < 0.01; 95% CI: −2.54 to −1.23).Conclusion: This study underscores the significant improvements in depression and cognitive function, and overall quality of life in individuals with mild to moderate AD. Additionally, the intervention alleviated caregiver burden, highlighting its potential as an effective mind-body approach for AD management.